Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology

The Cellular Signal: How PIK3R1 Mutations Affect Your Body

At a Glance

PIK3R1 mutations can disrupt the cell pathway that responds to insulin and growth factors. This may cause insulin resistance and partial loss of body fat, even when the body makes these hormones and blood fat levels are normal.

Understanding the biology of your condition requires looking deep inside the cell to a communication network called the PI3K-AKT pathway. In a healthy body, this pathway acts like a high-speed relay team that carries instructions from the outside of the cell to the inside, telling the cell when to grow, when to divide, and how to process sugar (glucose) [1][2].

The Relay Team: PI3K-AKT Signaling

When you eat, your body releases insulin. You also have growth factors like IGF-1 (Insulin-like Growth Factor 1) circulating in your blood [3]. These hormones act like “mail carriers” delivering important messages to your cells.

  1. The Docking Station: The hormone binds to a receptor on the surface of the cell [1].
  2. The Relay Switch: This binding activates adapter proteins that interact with a regulatory enzyme called PI3K (Phosphoinositide 3-kinase).
  3. The Messenger: PI3K then creates a chemical signal that activates another protein called AKT [1][3].
  4. The Result: Once AKT is activated, it performs several jobs: it opens “gates” to let sugar into the cell, tells the cell to store fat, and triggers growth [4][5].

The Role of the PIK3R1 Gene

The PIK3R1 gene provides the instructions for making a protein called p85α. This protein is a critical regulatory subunit of the PI3K enzyme [6]. Its job is to interact with adapter proteins and properly regulate the signaling relay.

In your case, a pathogenic variant in the PIK3R1 gene alters the function of the p85α protein [7]. Because of this change, the PI3K enzyme does not regulate the signal normally. It is not that the cell is completely “deaf”, but rather the relay system is impaired. The signal is sent by the hormone, but it is not processed efficiently inside the cell [6][8]. The functional effect depends on the particular variant.

Signaling Defect vs. Hormone Deficiency

It is very important to distinguish this condition from typical growth hormone deficiency (GHD).

  • In GHD: The body simply doesn’t make enough growth hormone. The “mail carriers” are missing, but the cells are perfectly capable of reading the messages if they were delivered [9].
  • In PIK3R1 Mutations: Your body often produces insulin and growth factors, but the cells process the signal inefficiently [10][11]. (Note: Hormone levels can vary greatly among individuals; some may have high insulin to compensate, while others may have altered growth hormone levels. Laboratory evaluation is highly individual.)

Because the primary issue lies within the cell’s signaling pathway rather than a simple lack of the hormone itself, treating the condition by adding more growth hormone is complex and may not work the same way it does for other patients [11].

Why This Leads to Fat Loss and Insulin Resistance

The breakdown in this signaling pathway has two major metabolic associations:

1. Risk of Insulin Resistance
Since the PI3K-AKT pathway is the primary way insulin tells cells to take in sugar, an impairment here makes the process less efficient [10]. Even when the body produces higher amounts of insulin to compensate, the cells still struggle to process the command to absorb sugar [12]. This can lead to very high insulin levels in the blood and increases the risk of early-onset diabetes, though diabetes risk and age of onset vary widely [13][6].

2. Partial Lipoatrophy (Fat Loss)
The same pathway is required for adipogenesis—the process of creating and maintaining fat cells [4]. Without a strong PI3K signal, the body cannot properly develop fat tissue in certain areas, particularly under the skin of the face and limbs [14]. This results in lipoatrophy (loss of fat), which gives the appearance of being very lean [10][15]. Interestingly, unlike other forms of lipodystrophy, people with PIK3R1 mutations may have normal levels of fats (lipids) in their blood, which is a feature doctors may use to help identify the condition, though regular monitoring remains necessary [15][16].

Common questions in this guide

What does a PIK3R1 mutation do inside my cells?
A PIK3R1 mutation can change the p85-alpha part of the PI3K enzyme and weaken the cell’s insulin-signaling relay. Insulin may still be present, and sometimes elevated, but cells may not process its message efficiently enough to take in glucose.
How is PIK3R1-related lipodystrophy different from growth hormone deficiency?
In growth hormone deficiency, the body does not make enough growth hormone. In PIK3R1-related lipodystrophy, the main problem is that cells may process hormone signals inefficiently, and hormone levels can vary between people.
Why can this condition cause loss of body fat?
The PI3K-AKT pathway helps the body create and maintain fat cells. When this signaling is impaired, less fat tissue may develop under the skin, especially in the face and limbs, causing partial lipoatrophy and a very lean appearance.
Could PIK3R1-related lipodystrophy lead to diabetes?
It can increase insulin resistance and lead to high insulin levels or diabetes at a younger age because cells may not respond efficiently to insulin. The risk and age of onset vary widely, so glucose and insulin should be monitored according to the care team’s plan.
Can my blood fat levels be normal despite having lipodystrophy?
Yes. Some people with PIK3R1-related lipodystrophy have normal blood lipid levels, unlike people with some other forms of lipodystrophy. Normal lipids do not remove the need for ongoing metabolic monitoring.
Would growth hormone or metformin be used to treat this condition?
There is no single treatment plan based on the gene result alone. Growth hormone may not correct a problem in cellular signaling, and metformin may be considered for insulin resistance in some people; an endocrinologist should decide based on hormone levels, glucose results, and overall health.

Get notified when new evidence is published on Lipodystrophy due to peptidic growth factors deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    HM-Chromanone, a Major Homoisoflavonoid in Portulaca oleracea L., Improves Palmitate-Induced Insulin Resistance by Regulating Phosphorylation of IRS-1 Residues in L6 Skeletal Muscle Cells.

    Park JE, Han JS

    Nutrients 2022; (14(18)) doi:10.3390/nu14183815.

    PMID: 36145191
  2. 2

    IGF1 receptor signaling pathways.

    Hakuno F, Takahashi SI

    Journal of molecular endocrinology 2018; (61(1)):T69-T86.

    PMID: 29535161
  3. 3

    Akt activation: A potential strategy to ameliorate insulin resistance.

    Zhang Z, Liu H, Liu J

    Diabetes research and clinical practice 2019; (156()):107092 doi:10.1016/j.diabres.2017.10.004.

    PMID: 29111280
  4. 4

    miR-100-3p inhibits the adipogenic differentiation of hMSCs by targeting PIK3R1 via the PI3K/AKT signaling pathway.

    Wang T, Zhong D, Qin Z, et al.

    Aging 2020; (12(24)):25090-25100 doi:10.18632/aging.104074.

    PMID: 33221758
  5. 5

    Insulin/IGF-1 enhances intestinal epithelial crypt proliferation through PI3K/Akt, and not ERK signaling in obese humans.

    Zhou W, Rowitz BM, Dailey MJ

    Experimental biology and medicine (Maywood, N.J.) 2018; (243(11)):911-916 doi:10.1177/1535370218785152.

    PMID: 29950119
  6. 6

    PIK3R1 mutations in individuals with insulin resistance or growth retardation: Case series and in silico functional analysis.

    Takayoshi T, Hirota Y, Sugano A, et al.

    Journal of diabetes investigation 2025; (16(8)):1526-1534 doi:10.1111/jdi.70062.

    PMID: 40420664
  7. 7

    The Role of PIK3R1 in Metabolic Function and Insulin Sensitivity.

    Tsay A, Wang JC

    International journal of molecular sciences 2023; (24(16)) doi:10.3390/ijms241612665.

    PMID: 37628845
  8. 8

    The metabolically protective energy expenditure increase of Pik3r1-related insulin resistance is not explained by Ucp1-mediated thermogenesis.

    Luijten I, Onishi A, McKay EJ, et al.

    American journal of physiology. Endocrinology and metabolism 2025; (328(6)):E743-E755 doi:10.1152/ajpendo.00449.2024.

    PMID: 40152560
  9. 9

    Growth Hormone Deficiency in Children: From Suspecting to Diagnosing.

    Vyas V, Kumar A, Jain V

    Indian pediatrics 2017; (54(11)):955-960 doi:10.1007/s13312-017-1190-3.

    PMID: 29217803
  10. 10

    PI3-kinase mutation linked to insulin and growth factor resistance in vivo.

    Winnay JN, Solheim MH, Dirice E, et al.

    The Journal of clinical investigation 2016; (126(4)):1401-12.

    PMID: 26974159
  11. 11

    KBTBD2 controls bone development by regulating IGF-1 signaling during osteoblast differentiation.

    Xun Y, Jiang Y, Khalid A, et al.

    Cell death and differentiation 2025; (32(6)):1099-1111 doi:10.1038/s41418-024-01416-0.

    PMID: 39562829
  12. 12

    Clinical characteristics of insulin resistance syndromes: A nationwide survey in Japan.

    Takeuchi T, Ishigaki Y, Hirota Y, et al.

    Journal of diabetes investigation 2020; (11(3)):603-616 doi:10.1111/jdi.13171.

    PMID: 31677333
  13. 13

    Metformin paradoxically worsens insulin resistance in SHORT syndrome.

    Lewandowski KC, Dąbrowska K, Brzozowska M, et al.

    Diabetology & metabolic syndrome 2019; (11()):81 doi:10.1186/s13098-019-0477-z.

    PMID: 31583022
  14. 14

    Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: toward recommendation for molecular testing and management.

    Avila M, Dyment DA, Sagen JV, et al.

    Clinical genetics 2016; (89(4)):501-506 doi:10.1111/cge.12688.

    PMID: 26497935
  15. 15

    Truncation of Pik3r1 causes severe insulin resistance uncoupled from obesity and dyslipidaemia by increased energy expenditure.

    Kwok A, Zvetkova I, Virtue S, et al.

    Molecular metabolism 2020; (40()):101020 doi:10.1016/j.molmet.2020.101020.

    PMID: 32439336
  16. 16

    Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.

    Huang-Doran I, Tomlinson P, Payne F, et al.

    JCI insight 2016; (1(17)):e88766.

    PMID: 27766312

This page is for informational purposes only and does not constitute medical advice. Your endocrinologist or genetics specialist can interpret PIK3R1 testing, hormone levels, and treatment options for you or your child.